Company intelligence / Profile preview
Autolus Therapeutics plc
London, United Kingdomautolus.com ↗
- Ownership
- Public · AUTL
- Employees
- ~650
- Development stage
- Other
01
Overview
Autolus received FDA approval for AUCATZYL (obecabtagene autoleucel) in November 2024 for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). In the FELIX study, the therapy showed complete remission in 63% of efficacy evaluable patients, with 42% achieving complete remission within three months and a median duration of response of 14.1 months. The therapy demonstrated a favorable safety profile with low levels of cytokine release syndrome.
- Therapeutic areas
- OncologyImmunology
- Modalities
- CAR T-cell therapiesProgrammed T cell therapies
- Industry
- Biotech
02
Drug pipeline
26 assets25 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $335.4M
- Total revenue
- $75.6M
- Enterprise value
- $217.2M
Beyond the preview
Go deeper on Autolus Therapeutics plc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autolus Therapeutics plc.